TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2193273
Drug: Daily objective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily objective uterine activity data
Study: 358765
Drug: Ferro-Retard (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferro-Retard (100 mg ferrous sulphate)
Study: 358765
Drug: Ferro-Retard (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferro-Retard (100 mg Fe2+)
Study: 12520172
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release tablets
Study: 358765
Drug: Placebo, rapidly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, rapidly disintegrating and sustained release ferrous sulphate tablets
Study: 31786869
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and nimotuzumab combined with concurrent chemoradiotherapy
Study: 31786869
Drug: Cisplatin combined
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin combined with concurrent chemoradiotherapy
Study: 25483419
Drug: Intravenous labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous labetalol (L)
Study: 25483419
Drug: Intravenous hydralazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydralazine (H)
Study: 18332608
Drug: Pitavastatin treatment
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin treatment
Study: 16279903
Drug: 4.8 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.8 g/day mesalamine (800 mg tablet)
Study: 16279903
Drug: 2.4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g/day mesalamine (400 mg tablet)
Study: 8142092
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of epidural morphine
Study: 3150126
Drug: Magnesium Valproate
Normalized name: magnesium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium Valproate (Mg VPA)
Study: 25595308
Drug: Standard fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fluid therapy (Control)
Study: 23750460
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioral treatment based on exposure exercises (ICBT)
Study: 21915490
Drug: Multidisciplinary rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary rehabilitation program (12-week stimulation and psychoeducational program, administered twice a week during 6.5-hour gatherings)
Study: 30450213
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity interval training (HIIT) on a cycle ergometer, thrice weekly for 8 weeks
Study: 30450213
Drug: Weekly contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly contact with investigators
Study: 23877339
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate (1.4 mg/m², 2-5 min intravenous on days 1 and 8)
Study: 23877339
Drug: Ixabepilone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixabepilone (40 mg/m², 3 h intravenous on day 1)
Study: 19919966
Drug: Home orthostatic
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home orthostatic training (HOT) for 40 min daily for 6 months
Study: 19919966
Drug: Sham training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham training for 10 min daily for 6 months
Study: 18426147
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (NS) plus loratadine, 200 microg + 10 mg
Study: 18426147
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (NS), 200 microg
Study: 16682384
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet therapy (aspirin, clopidogrel 300 mg, and Tirofiban)
Study: 16682384
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (aspirin, clopidogrel 600 mg)
Study: 22186694
Drug: Sandostatin LAR
Normalized name: Sandostatin LAR
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sandostatin LAR 30 mg injection once every 4 weeks for 6 doses (n = 35)
Study: 7617237
Drug: Dobutamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine infusion at 3 mu/kg/min, started before anesthesia and modulated during the operation based on monitoring values.
Study: 7617237
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no dobutamine infusion), underwent the same anesthesiological procedure without receiving the drug.
Study: 1978487
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release (CR) 400 mg once daily
Study: 1978487
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release (IR) 200 mg twice daily
Study: 29401353
Drug: Transcendental Meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcendental Meditation (TM) practice; full-dose (two 20-min sessions per day) and half-dose (one 20-min session per day) groups.
Study: 29401353
Drug: Transcendental Meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcendental Meditation (TM) practice; full-dose group vs half-dose group.
Study: 24124961
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec and insulin aspart (IDegAsp)
Study: 19778808
Drug: L-thyroxine (6.25-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine (6.25-25 microg daily)
Study: 15908661
Drug: GemOx (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GemOx (gemcitabine 1 g/m2 as a 100‐minute infusion on day 1 and oxaliplatin 100 mg/m2 as a 2‐hour infusion on day 2 every 2 weeks)
Study: 15908661
Drug: Gem (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gem (gemcitabine 1 g/m2 as a weekly 30‐minute infusion)
Study: 9617916
Drug: Bromocriptine (DA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (DA agonist)
Study: 9617916
Drug: Fenfluramine (serotonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (serotonin agonist)
Study: 144842
Drug: SH B
Normalized name: BSH BTC
DrugBank: Dental Mesenchymal Pulp Stem Cells (DB15737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SH B 209 AB (antiandrogen preparation containing cyproterone acetate)
Study: 144842
Drug: Neogynon (ovulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neogynon (ovulation inhibitor with no antiandrogenic effect)
Study: 28866652
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day folic acid
Study: 28866652
Drug: 0.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/day folic acid
Study: 26521569
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with acupoint injection of nerve growth factor (NGF), 0.5 mL each acupoint, once a day for 7 days, 3 sessions total
Study: 26521569
Drug: Intravenous drop
Normalized name: Amoxi Drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous drop of citicoline sodium and intramuscular injection of NGF, treatment for 7 days, 3 sessions total
Study: 16897661
Drug: Structured Treatment
Normalized name: Lipid,structured (From Sunflower Oil)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured Treatment Interruption (STI)
Study: 2487532
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of ibopamine
Study: 27046443
Drug: Skin/subcutaneous hypoperfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin/subcutaneous hypoperfusion on ICG-FA
Study: 25044423
Drug: Curcumin capsules
Normalized name: curcumin Oral Capsule
DrugBank: Curcumin sulfate (DB14635)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin capsules
Study: 12679437
Drug: Glyburide therapy
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide therapy
Study: 21542122
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous n-acetylcysteine (1,200 mg bolus followed by 200 mg/hr for 24 hr; n = 206)
Study: 21542122
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous n-acetylcysteine
Study: 11467630
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg erythromycin (Er50)
Study: 11467630
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg erythromycin (Er100)
Study: 9812643
Drug: Xianzhen tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xianzhen tablet
Study: 7959083
Drug: Vitamin C,
Normalized name: Vitamin C, sodium salt
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C, 250 mg twice daily
Study: 7959083
Drug: Placebo, one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, one capsule twice daily
Study: 3652479
Drug: Pirenzepine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (100 mg orally at 2200 and 2400 h)
Study: 29617737
Drug: 200 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 µg/kg ivermectin
Study: 29617737
Drug: 600 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 µg/kg ivermectin
Study: 20863389
Drug: 40 mg/m²
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/m² Cisplatin (group I; 16 patients)
Study: 20863389
Drug: 50 mg/m²
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/m² Paclitaxel (group II; 15 patients)
Study: 18395723
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones (135 mg daily for 6 months)
Study: 14551299
Drug: Standard timed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard timed (ST) doxorubicin 60 mg/m2 plus cisplatin 60 mg/m2
Study: 14551299
Drug: Circadian timed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circadian timed (CT) doxorubicin 60 mg/m2 at 6:00 am plus cisplatin 60 mg/m2 at 6:00 pm
Study: 10529079
Drug: Intracoronary papaverine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary papaverine (10 mg)
Study: 4033706
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (268 g per day)
Study: 4033706
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (19 g per day)
Study: 23897038
Drug: ondansetron (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (4 mg/kg of body weight twice daily)
Study: 16601642
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment plus family psychoeducation
Study: 11191690
Drug: Fluvoxamine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine with behavior therapy (20 sessions)
Study: 1449045
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (hGH) 0.1 IU.kg‐1 body weight.d‐1
Study: 1449045
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (hGH)
Study: 3904700
Drug: Alternative healing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative healing agents
Study: 25371275
Drug: NSAID patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID patch (ketoprofen)
Study: 25371275
Drug: NSAID patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID patch + TENS
Study: 25371275
Drug: NSAID patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID patch + heating pad
Study: 25371275
Drug: NSAID patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID patch + topical capsaicin
Study: 22260861
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid mixture beverage (CHO/AA) consisting of 0.088 g cystine 2HCl, 0.043 g methionine, 0.086 g valine, 12.094 g isoleucine, 0.084 g leucine, and 100 g dextrose
Study: 22260861
Drug: Control beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control beverage (CHO) consisting of 100 g dextrose only
Study: 20230319
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg plain bupivacaine
Study: 20230319
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg hyperbaric ropivacaine with fentanyl 20 μg
Study: 20230319
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg plain ropivacaine with fentanyl 20 μg
Study: 17053207
Drug: Salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone propionate (50/500 micro g) twice daily
Study: 17053207
Drug: Salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (50 micro g) twice daily
Study: 1496838
Drug: CO2-bathing series
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2-bathing series with light-motion therapy
Study: 6648053
Drug: Combined regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined regimen (2-mg tablet of salbutamol + 10 puffs of salbutamol inhalation)
Study: 6648053
Drug: Salbutamol inhalation
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol inhalation (100 micrograms per puff)
Study: 6648053
Drug: Salbutamol tablet
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol tablet
Study: 6648053
Drug: Placebo (tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (tablet and inhalation)
Study: 25222428
Drug: CPAP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP and standard therapy
Study: 10577754
Drug: Intra-articular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular morphine
Study: 24952044
Drug: Intra-articular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular morphine and lidocaine
Study: 21909946
Drug: Visual feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual feedback (visualization of charts showing the progression of disease activity parameters) added to DMARDs therapy
Study: 18453320
Drug: Oat cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat cereal (5.7 g/day beta-glucan)
Study: 7297020
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg carteolol
Study: 7297020
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg carteolol
Study: 7297020
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg carteolol
Study: 7297020
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg carteolol
Study: 31270291
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec U100 (IDeg)
Study: 31270291
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine U100 (IGla)
Study: 24954805
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment (paclitaxel then UFT)
Study: 24954805
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment (paclitaxel then S-1)
Study: 24954805
Drug: UFT monotherapy
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT monotherapy
Study: 23098579
Drug: Conventional radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiotherapy (CR) - 25 × 2 Gy over 5 weeks, with a sequential boost of 8 × 2 Gy over 2 weeks for BCS patients
Study: 26711755
Drug: Daptomycin 6
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin 6 mg/kg/day
Study: 19730900
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (vancomycin 1 g every 12 h or antistaphylococcal penicillin 2 g every 4 h, both with gentamicin 1 mg/kg every 8 h for 4 days)
Study: 7810090
Drug: Iso‐Mack retard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iso‐Mack retard + Moduretic (diuretic)
Study: 30001923
Drug: Fingolimod 0.5
Normalized name: fingolimod 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 0.5 mg once-daily
Study: 28634650
Drug: Z-360 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z-360 60 mg
Study: 28634650
Drug: Z-360 120
Normalized name: Z-160
DrugBank: Z-160 (DB12743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z-360 120 mg
Study: 28634650
Drug: Z-360 240
Normalized name: Z-160
DrugBank: Z-160 (DB12743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z-360 240 mg
Study: 20438578
Drug: PEG‐IFN monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN monotherapy at a dosage of 0.8 μg/kg per week (n = 12)
Study: 20438578
Drug: PEG‐IFN (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN (0.8 μg/kg per week) plus RIB (800‐1200 mg/d) (n = 12)
Study: 23274785
Drug: PEG‐IFN monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN monotherapy
Study: 12869355
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg 17beta‐estradiol orally + 100 mg progesterone daily
Study: 12869355
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg 17beta‐estradiol transdermally per day + 100 mg progesterone daily
Study: 12869355
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + 100 mg progesterone daily
Study: 8249953
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (10 micrograms) at 0, 1, 2, and 11 months of age with hepatitis B immune globulin (0.5 mL/kg) within 2 hours of birth (group A)
Study: 8249953
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (10 micrograms) at 3, 4, 5, and 11 months of age with hepatitis B immune globulin (0.5 mL/kg) within 2 hours of birth and a second dose at 3 months (group B)
Study: 27362497
Drug: Standard intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intervention arm (one weekly exercise session for six weeks)
Study: 24111649
Drug: Glycerin suppository
Normalized name: Leader Pediatric Glycerin Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerin suppository (half every twelve hours) and phototherapy
Study: 22227086
Drug: Protocol-based weaning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol-based weaning (PBW) administered by nurses, n = 61
Study: 15817848
Drug: Medium dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dairy group (calcium intake of approximately 1000-1100 mg/d)
Study: 15817848
Drug: High dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dairy group (calcium intake of 1300-1400 mg/d)
Study: 1958561
Drug: TE-300 mg/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: TE-300 mg/wk
Study: 1958561
Drug: ND-300 mg/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: ND-300 mg/wk
Study: 1958561
Drug: TE-100 mg/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: TE-100 mg/wk
Study: 6765140
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid and dipyridamol (1,050 mg + 150 mg/day) - group A
Study: 6765140
Drug: Pentoxifylline (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (1,200 mg/day) - group P
Study: 30704260
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (n=155)
Study: 27922936
Drug: TX‐004HR (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: TX‐004HR (all doses)
Study: 23444285
Drug: Modified-release prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release prednisone tablets (5 mg) taken at bedtime
Study: 23444285
Drug: Conventional prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional prednisone (5 mg)
Study: 23444285
Drug: Modified-release prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release prednisone tablets taken with or after an evening meal
Study: 23444285
Drug: Modified-release prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release prednisone tablets taken under fasted conditions
Study: 21833690
Drug: Integrated behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated behavioral and family therapy (IBFT)
Study: 16930803
Drug: 4 x
Normalized name: Mepilex AG 4 x 4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x 5 mg cetrorelix acetate
Study: 16930803
Drug: 4 x
Normalized name: Mepilex AG 4 x 4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x 10 mg cetrorelix acetate
Study: 16930803
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 10 mg cetrorelix acetate
Study: 12063916
Drug: Adjuvant chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemoradiation therapy
Study: 782969
Drug: Recombinant WRL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant WRL 105 live attenuated influenza virus vaccine
Study: 782969
Drug: Neither vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither vaccine nor placebo
Study: 23546328
Drug: Disinfection with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disinfection with 70% alcohol and 1% iodine solutions
Study: 19421678
Drug: Oral water
Normalized name: Oral Wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral water soluble contrast agent (Group A)